TECH · BIO-TECHNE Corp

$71.60 -0.17 (-0.24%) At close · Jul 24

Market Cap

$11.21B

156.57M

Trades by corporate insiders — officers, directors and holders of more than 10% of the shares — disclosed to the SEC on Forms 3, 4 and 5. Form 4 must be filed within two business days of the trade.

Insider Sentiment Score

Peer-relative 0–100 rank of how aggressively insiders accumulated over the trailing 90 days. See the full ranking.

Net buyers

-1

Net shares bought

0.00%

Net buy value

-$320,386

Date	Insider	Role	Type	Security	Shares	Price	Value	After
2026-06-02	Crouse Steven C.	Director	Convert↑ Filing footnotes — Common Stock (Direct) Each restricted stock unit represents a contingent right to receive one share of Bio-Techne common stock. Due to a mathematical error on the Form 4 filed May 5, 2026, the number of shares beneficially owned is being increased by 40 shares and this filing represents the correct number of shares beneficially owned by the Reporting Person.	Common Stock	600	—	—	6,977
2026-06-02	Crouse Steven C.	Director	Tax↓	Common Stock	216	$49.77	$10,750	6,761
2026-06-02	Crouse Steven C.	Director	Convert↓ Filing footnotes — Restricted Stock Units (Direct) Each restricted stock unit represents a contingent right to receive one share of Bio-Techne common stock. 600 restricted stock units vest on each of 6/2/2026, 6/2/2027 and 6/2/2028.	Restricted Stock Units	600	—	—	1,200
2026-05-08	Herr Amy E.	Director	Convert↓ Filing footnotes — Stock Option (Right to Buy) (Indirect) Fully vested.	Stock Option (Right to Buy) (I)	6,636	—	—	0
2026-05-08	Herr Amy E.	Director	Convert↑	Common Stock (I)	6,636	$47.60	$315,874	6,836
2026-05-08	Herr Amy E.	Director	Sell↓ Filing footnotes — Common Stock (Indirect) The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $48.19 to $48.31, inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.	Common Stock (I)	6,636	$48.28	$320,386	200
2026-05-05	Bohnen Shane	SVP - General Counsel	Tax↓	Common Stock	7,055	$56.68	$399,877	7,249
2026-05-05	Bohnen Shane	SVP - General Counsel	Convert↓ Filing footnotes — Stock Option (Right to Buy) (Direct) Fully exercisable.	Stock Option (Right to Buy)	8,400	—	—	448
2026-05-05	Kelderman Kim	Director	Tax↓	Common Stock	23,951	$56.68	$1,357,543	65,799
2026-05-05	Kelderman Kim	Director	Convert↑	Common Stock	26,692	$47.60	$1,270,539	89,750
2026-05-05	Hippel James	CFO	Convert↓ Filing footnotes — Stock Options (Right to Buy) (Direct) Fully exercisable.	Stock Options (Right to Buy)	62,000	—	—	62,068
2026-05-05	Bohnen Shane	SVP - General Counsel	Convert↑	Common Stock	8,400	$47.60	$399,840	14,304
2026-05-05	Hippel James	CFO	Tax↓	Common Stock	56,955	$56.68	$3,228,209	153,670
2026-05-05	Hippel James	CFO	Convert↑	Common Stock	62,000	$47.60	$2,951,200	210,625
2026-05-05	Kelderman Kim	Director	Convert↓ Filing footnotes — Stock Option (Right to Buy) (Direct) Fully exercisable.	Stock Option (Right to Buy)	26,692	—	—	35,000
2026-05-01	Crouse Steven C.	Director	Convert↑ Filing footnotes — Common Stock (Direct) Each restricted stock unit represents a contingent right to receive one share of Bio-Techne common stock.	Common Stock	794	—	—	6,688
2026-05-01	Crouse Steven C.	Director	Convert↓ Filing footnotes — Restricted Stock Units (Direct) Each restricted stock unit represents a contingent right to receive one share of Bio-Techne common stock. 794 restricted stock units vest on 5/1/2026 and 5/1/2027.	Restricted Stock Units	794	—	—	794
2026-05-01	Crouse Steven C.	Director	Tax↓	Common Stock	311	$55.02	$17,111	6,337
2026-04-22	Kelderman Kim	Director	Convert↓ Filing footnotes — Stock Option (Right to Buy) (Direct) Fully exercisable.	Stock Option (Right to Buy)	11,344	—	—	61,692
2026-04-22	Kelderman Kim	Director	Convert↑	Common Stock	11,344	—	—	64,421
2026-04-22	Hippel James	CFO	Convert↑	Common Stock	62,000	—	—	204,722
2026-04-22	Hippel James	CFO	Convert↓ Filing footnotes — Stock Options (Right to Buy) (Direct) Fully exercisable.	Stock Options (Right to Buy)	62,000	—	—	124,068
2026-04-22	Kelderman Kim	Director	Tax↓	Common Stock	1,363	$58.58	$79,845	63,058
2026-04-22	Hippel James	CFO	Tax↓	Common Stock	56,097	$58.58	$3,286,162	148,625
2026-04-14	Kelderman Kim	Director	Convert↓ Filing footnotes — Stock Option (Right to Buy) (Direct) Fully exercisable.	Stock Option (Right to Buy)	36,500	—	—	73,036
2026-04-14	Kelderman Kim	Director	Tax↓	Common Stock	32,088	$58.66	$1,882,282	53,077
2026-04-14	Kelderman Kim	Director	Convert↑	Common Stock	36,500	—	—	85,165
2026-04-03	Bohnen Shane	SVP - General Counsel	Convert↓ Filing footnotes — Restricted Stock Units (Direct) Each restricted stock unit represents a contingent right to receive one share of Bio-Techne common stock. 2,259 restricted stock units vest on 4/3/2026.	Restricted Stock Units	2,259	—	—	0
2026-04-03	Bohnen Shane	SVP - General Counsel	Tax↓	Common Stock	740	$53.13	$39,316	5,904
2026-04-03	Bohnen Shane	SVP - General Counsel	Convert↑	Common Stock	2,259	—	—	6,644
2026-03-02	Crouse Steven C.	Director	Award↑ Filing footnotes — Stock Option (right to buy) (Direct) Options to purchase 478 shares vest on each of 3/2/2027, 3/2/2028 and 3/2/2030; and options to purchase 477 shares vest on 3/2/2029.	Stock Option (right to buy)	1,911	—	—	1,911
2026-03-02	Crouse Steven C.	Director	Award↑ Filing footnotes — Restricted Stock Units (Direct) Each restricted stock unit represents a contingent right to receive one share of Bio-Techne common stock. 245 restricted stock units vest on 3/2/2027, 3/2/2028 and 3/2/2029.	Restricted Stock Units	735	—	—	735
2026-03-02	Crouse Steven C.	Director	Award↑ Filing footnotes — Performance Restricted Stock Units (Direct) Each restricted stock unit represents a contingent right to receive one share of Bio-Techne common stock. Vests in full or in part on 8/15/2028 if certain performance goals are achieved (or such later date as performance is certified by the Administrator).	Performance Restricted Stock Units	2,387	—	—	2,387
2026-02-17	Herr Amy E.	Director	Sell↓ Filing footnotes — Common Stock (Indirect) The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $59.091 to $59.1390, inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.	Common Stock (I)	1,976	$59.11	$116,791	200
2026-02-03	Herr Amy E.	Director	Tax↓	Common Stock (I)	16	$64.63	$1,034	2,176
2026-02-03	Herr Amy E.	Director	Convert↑	Common Stock (I)	38	—	—	2,192
2026-02-03	Herr Amy E.	Director	Convert↓ Filing footnotes — Restricted Stock Units (Indirect) Each restricted stock unit represents a contingent right to receive one share of Bio-Techne common stock. 38 restricted stock units vest on each of 2/3/2026 and 2/3/2027, and 39 restricted stock units vest on 2/3/2028.	Restricted Stock Units (I)	38	—	—	77
2026-02-01	McManus Matthew	EVP & Chief Operating Officer	Convert↓ Filing footnotes — Restricted Stock Units (Direct) Each restricted stock unit represents a contingent right to receive one share of Bio-Techne common stock. 4,621 restricted stock units vest on 2/1/2026 and 4,620 restricted stock units vest on 2/1/2027.	Restricted Stock Units	4,621	—	—	4,620
2026-02-01	McManus Matthew	EVP & Chief Operating Officer	Convert↑	Common Stock	4,621	—	—	9,356
2026-02-01	McManus Matthew	EVP & Chief Operating Officer	Tax↓	Common Stock	1,665	$64.09	$106,710	7,691
2025-11-03	Hippel James	CFO	Convert↑	Common Stock	13,159	—	—	143,042
2025-11-03	Hippel James	CFO	Convert↓ Filing footnotes — Restricted Stock Units (Direct) Each restricted stock unit represents a contingent right to receive one share of Bio-Techne Corporation common stock. 13,159 restricted stock units vest on 11/1/2025.	Restricted Stock Units	13,159	—	—	0
2025-11-03	Hippel James	CFO	Tax↓	Common Stock	11,865	$62.57	$742,393	142,722
2025-11-03	Geist William	PRESIDENT, PROTEIN SCIENCES	Convert↑	Common Stock	9,911	—	—	25,023
2025-11-03	Hippel James	CFO	Convert↓ Filing footnotes — Restricted Stock Units (Direct) Each restricted stock unit represents a contingent right to receive one share of Bio-Techne Corporation common stock. 11,545 restricted stock units vest on each of 11/1/2025 and 11/1/2026; and 11,544 restricted stock units vest on 11/1/2027.	Restricted Stock Units	11,545	—	—	23,089
2025-11-03	Hippel James	CFO	Convert↑	Common Stock	11,545	—	—	154,587
2025-11-03	Geist William	PRESIDENT, PROTEIN SCIENCES	Tax↓	Common Stock	4,520	$62.57	$282,816	20,503
2025-11-03	Kelderman Kim	Director	Tax↓	Common Stock	2,303	$62.57	$144,099	48,665
2025-11-03	Geist William	PRESIDENT, PROTEIN SCIENCES	Convert↓ Filing footnotes — Restricted Stock Units (Direct) Each restricted stock unit represents a contingent right to receive one share of Bio-Techne common stock. 9,911 restricted stock units vest on 11/1/2025.	Restricted Stock Units	9,911	—	—	0
2025-10-30	BAUMGARTNER ROBERT V	Director	Award↑	Common Stock	1,640	—	—	46,503

Legend Buy — open-market purchase Sell — open-market sale ↑ Shares acquired ↓ Shares disposed (gift, conversion, tax…)

Showing 1–50 of 768 transactions

Key facts CIK 842023 CUSIP 09073M104 13F (30d) 118 filings 118 filers Visit website Investor relations